Clinical Trial Results:
A phase II, multicentre study of oral LBH589 in patients with accelerated phase or blast phase (blast crisis) chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors
Summary
|
|
EudraCT number |
2006-002011-27 |
Trial protocol |
BE DK FR DE NL IT |
Global completion date |
26 Aug 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Aug 2016
|
First version publication date |
29 Aug 2016
|
Other versions |
|
Summary report(s) |
CLBH589B2211.CTR.11Aug2016 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.